Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Operating Margin (2020 - 2025)

Historic Operating Margin for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to 9.05%.

  • Xeris Biopharma Holdings' Operating Margin rose 328100.0% to 9.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.68%, marking a year-over-year increase of 277900.0%. This contributed to the annual value of 16.57% for FY2024, which is 102800.0% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Operating Margin of 9.05% as of Q3 2025, which was up 328100.0% from 6.27% recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Operating Margin high stood at 9.05% for Q3 2025, and its period low was 289.55% during Q2 2021.
  • Over the past 5 years, Xeris Biopharma Holdings' median Operating Margin value was 40.0% (recorded in 2023), while the average stood at 75.37%.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Operating Margin tumbled by -740800bps in 2021, and later soared by 2148000bps in 2022.
  • Over the past 5 years, Xeris Biopharma Holdings' Operating Margin (Quarter) stood at 225.26% in 2021, then skyrocketed by 80bps to 45.77% in 2022, then skyrocketed by 52bps to 22.17% in 2023, then surged by 113bps to 2.79% in 2024, then skyrocketed by 224bps to 9.05% in 2025.
  • Its last three reported values are 9.05% in Q3 2025, 6.27% for Q2 2025, and 5.14% during Q1 2025.